Ahmad, S. 2010. Pathogenesis, Immunology and Diagnosis of Latent Mycobacterium tuberculosis Infection. Clinical and Developmental Immunology. 2011 (1) : 1-17.
Al-Mutairi, N.M., Ahmad, S. Mokaddas, E. 2011. First Report of Molucular Detection of Fluoroquinolone Resistance-Associated gray Mutations in Multidrug-Resistance Clinical Mycobacterium tuberculosis Isolat in Kuwait. BMC Research Notes. 4 (123) : 1-7
Astuti, V, D. 2008. Deteksi mutasi gen gyrA dan gyrB pada isolat sampel extensively drug resistance Mycobacterium tuberculosis (XDR-TB) di rumah sakit paru Dr HA Rotinsulu Bandung. Master's Thesis. Sekolah Ilmu dan Teknologi Hayati-Institut Teknologi Bandung, Bandung
Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM (2006).
Novel gyrase mutations in quinolone-resistan and -hypersusceptible clinical isolats of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother. 50 : 104-112.
Avalos, E., Catanzaro, D., Catanzaro, A et al. 2015. Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium tuberculosis Isolat : A Systematic Review. PLoS ONE. 10 (3) : 1-24.
Ban˜uls, A,L., Sanou, A., Anh, N,T,V., Godreuil, S. 2015. Mycobacterium tuberculosis: Ecology and Evolution of A Human Bacterium. Journal of Medical Microbiology. 64 : 1261–1269.
Bravo, L, T, C., Tuohy, M.J., Ang, C., Destura, R.V., Mendoza, M., Procop, G.W.
2009. Pyrosequencing for Rapid Detection of Mycobacterium tuberculosis Resistance to Rifampin, Isoniazid, and Fluoroquinolones. Journal of Clinical Microbiology. 47 (12) : 3985–3990.
Budi, I, S., Ardillah, Y., Sari, I, P., Septiawati, D. 2018. Analisis Faktor Risiko Kejadian penyakit Tuberculosis Bagi Masyarakat Daerah Kumuh Kota Palembang. Jurnal Kesehatan Lingkungan Indonesia. 17 (2) : 87 – 94.
Chen, J., Chen, Z., Li, Y et al. 2012. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolat from Hubei Province, China. The Brazilian Journal Of Infection Disease. 16 (2) : 136-141.
Chernyaeva, E., Federova, E., Zhemkova, G et al. 2013. Characterization of Multiple and Extensively Drug Resistan Mycobacterium tuberculosisIsolats With Different Ofloxacin-Resistance Levels.
Tuberculosis. 93 (3) : 291-295.
Chien, J,Y., Chiu, W,Y., Chien, S,T et al. 2016. Mutations in gyrA and gyrB Among Fluoroquinolone and Multidrug-Resistance Mycobacterium tuberculosis Isolat. Antimicrob Agents Chemother. 60 (4) :2090 –2096.
Cui, Z., Wang, J., Lu, J et al. 2011. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolats from East China in 2009. BMC Infectious Diseases. 11 (78) : 1-5.
Departemen Kesehatan Republik Indonesia. 2005. Pharmaceutical Care Untuk Penyakit Tuberkulosis. Direktorat Jenderal Bina Kefarmasian Dan Alat Kesehatan. Jakarta.
D’Argenio, D, A., Vetting, M, W., Ohlendorf, D, H et.al. 1999. Substitution, Insertion, Deletion, Suppression, and Altered Substrate Specificity in Functional Protocatechuate 3,4-Dioxygenases. Journal of bacteriology.
181 : 6478–6487.
Evans, J., Segal, H. 2010. Novel Multiplex Allele-Specific PCR Assays for The Detection of Resistance to Second-line Drug in Mycobacterium tuberculosis. J.Antimicrob Chemother. 65: 897-900.
Gupte, S. 1990. Mikrobiologi Dasar. Binarupa Aksara. Jakarta.
Hogan, C,A., Puri, L., Gore, G., Pai, M. 2017. Impact Of Fluoroquinolone Treatment On Delay Of Tuberculosis Diagnosis : A Systematic Review and Meta-Analysis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 6 : 1–7.
Irianti, T., Kuswandi, Yasin, N.M et al. 2016. Mengenal Anti-Tuberkulosis. Buku Anti-tuberkulosis.
Jnawali, H.N., Ryo, S. 2013. First and Second Line Drugs and Drug Resistance.
Tuberculosis - Current Issues in Diagnosis and Management. 10 : 163-180.
Kementerian Kesehatan Republik Indonesia. 2011. Rencana Aksi Nasional Public Private Mix Pengendalian Tuberkulosis Indonesia : 2011-2014.
Kementerian Kesehatan Republik Indonesia. Jakarta. Indonesia.
Kementerian Kesehatan Republik Indonesia. 2013. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Kementerian Kesehatan Republik Indonesia. Jakarta. Indonesia.
Kementerian Kesehatan Republik Indonesia. 2014. Pedoman Nasional Pengendalian Tuberkulosis. Kementerian Kesehatan Republik Indonesia.
Jakarta. Indonesia.
Kim, E,S., Hooper, D,C. 2014. Clinical Importance and Epidemiology Of Quinolone Resistance. Infect Chemother. 46 (4) : 226 – 238.
Kumari, R., Banerjee, T., Anupurba, S. 2017. Molecular Detection of Drug Resistance to Ofloxacin and Kanamycin in Mycobacterium tuberculosis by Using Multiplex Allele-Specific PCR. Journal of Infection and Public Health. 11 (1) : 54-58.
Lengar, P. 2012. An analysis of substitution, deletion and insertion mutations in cancer genes. Nucleic Acids Research. 40 (14) : 6401–6413.
Li, J., Gao, X., Luo, T et al. 2014. Association of gyrA/B Mutations and Resistance Level to Fluoroquinolone in Clinical Isolats of Mycobacterium tuberculosis. Emerging Microbes and Infections. 3 (3) : 1-5.
Loeffler, J., Steven, D.A. 2003. Antifungal Drug Resistance.Clinical Infections Disease. 36 (1) : 31-41.
Maruri, F., Sterling, T.R., Kaiga, A,W et al. 2012. A Systematic Review of Gyrase Mutations Associated With Fluoroquinolone-Resistance Mycobacterium tuberculosis and A Propose Gyrase Numbering System. J Antimicrob Chemother. 67 (1) : 819-831.
Matrat S, Aubry A, Mayer C, Jarlier V, Cambau E (2008). Mutagenesis in the α3α4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. Antimicrob Agents Chemother. 52 (8) : 2909-2914.
Mokrousov, I., Otten,T., Manicheva, Oet al. 2008. Molecular Characterization Of Ofloxacin-Resistan Mycobacterium tuberculosis Strains From Russia.
Antimicrobial agents and chemotherapy. 52 (8) : 2937–2939.
Nikaido, H. 2009. Multidrug-Resistance in Bacteria. Annual Review of Biochemistry. 78 (1) : 119-146.
Nosova, E.Y., Bukatina, A.A., Isaeva, Y.D et al. 2013. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. Journal of Medical Microbiology. 62 (1): 108–113.
Pantel, A., Petrella, S., Veziris, N et al. 2012. Extending the Definition of the gyrB Quinolone Resistance-Determining Region in Mycobacterium tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in M.
tuberculosis. Antimicrobial Agents and Chemotherapy. 56 (4) : 1990-1996.
Palomino, J.C., Martin, A. 2014.Drug Resistance Mechanisms in Mycobacterium tuberculosis.Antibiotics. 3 (3) : 317–340.
Perdigão, J., Macedo, R., Malaquias, A et al.2010. Genetic analysis of extensively drug-resistan Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother. 65 (2) : 224- 227.
Pitaksajjakul, P., Wongwit, W., Punprasit, W et al.2005. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistan Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health.
36 (4) : 228-237.
Saeed, M., Ahmad, M., Iram, S et al . 2017. GeneXpert technology: A breakthrough for the diagnosis of tuberculous pericarditis and pleuritis in less than 2 hours. Saudi Med J. 38 (7) : 699-705.
Soudani, A., Hadjfredj, S., Zribi, M et al. 2010. First report of molecular characterization of fluoroquinolone resistanMycobacterium tuberculosisisolats from a Tunisian hospital. Clin Microbiol Infect. 16 (9) : 1454–1457.
Siddiqi, N., Shamim, M., Hussain, Set al. 2002. Molecular characterization of multidrug-resistan isolats of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother. 46 (2) : 443-450.
Sirgel, F,A., Warren, R,M., Streicher, M et al. 2012. gyrA Mutations and Phenotypic Susceptibility Levels To Ofloxacin and Moxifloxacin In Clinical Isolat Of Mycobacterium tuberculosis. J Antimicrob Chemother.
67 (1) : 1088–1093.
Sjahrurachman, A. 2008. Kultur dan Uji Kepekaan Mycobacterium tuberculosis Terhadap Obat Anti Tuberkulosis Lini Pertama. Departemen Kesehatan RI. Jakarta.
Tanwar, J., Das, S., Fatima, Z., Hameed, S. 2014. Multidrug Resistance : An Emerging Crisis. Interdisciplinary Perspectives on Infectious Diseases.
2014 (1) : 1-7.
Tasnim, T., Tarafder, S., Alam, F.M et al. 2018. Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-TB) among Pulmonary Multidrug Resistan Tuberculosis (MDR-TB) Patients in Bangladesh. Journal of Tuberculosis Research. 6 (3) : 199-206.
Tretter, E.M., Schoeffier, A.J., Weisfield, S.R et al. 2010. Crystal Structure Of The DNA Gyrase gyrA N-Terminal Domain From Mycobacterium tuberculosis. Proteins. 78 (2) : 492–495.
World Health Organization. 2017. Global Tuberculosis Report 2017. France.
World Health Organization. 2018. What is MDR-TB.
Zhang, Z., Lu, J., Wang, Y et al. 2014. Prevalence and Molecular Characterization of FluoroquinoloneResistan Mycobacterium tuberculosis Isolats in China. Antimicrobial Agents and Chemotherapy. 58 (1) : 364-369.
Lampiran 1. Alat dan Bahan Penelitian Alat
Alat yang digunakan dalam penelitian ini antara lain : ose, tabung mc.cartney, mikropipet, tips steril, mesin PCR verity,nanophtometer, alat elektroforesis, tube 1,5ml, mikrotube, sentrifus, neraca digital, dry block, freezer -20°C, UV reader/gel documentation system, autoklaf dan biosafety cabinet (BSC).
Bahan
Bahan yang digunakan dalam penelitian ini antara lain isolat bakteri Mycobacterium tuberculosis resistan ofloxacin, media padat Lowenstein-Jensen, NaCl fisiologis, destilat water, akuades, etidium bromida 1%, TE buffer, TBE buffer, master mix, nuclease free water, DNA marker, primer gen gryA, primer gen gryA dan gryB dan agarose.
Lampiran 2. Hasil Uji Fenotip Isolat Klinis Mycobacterium tuberculosis No. Kode
Sampel Umur Kelamin Uji Sensitifitas OAT